CLAIMS

What is claimed is:

1. Oxcarbazepine Form B.

2. Oxcarbazepine having a PXRD diffraction pattern with peaks at about 11.9, 14.4, 20.0, 23.0, 25.1 ± 0.2 degrees two-theta.

3. The oxcarbazepine of claim **2** having a PXRD diffraction pattern with peaks at about 11.9, 14.4, 17.7, 19.4, 20.0, 21.1, 23.0, 24.0, 24.4 ,25.1, 26.0 ± 0.2 degrees two-theta.

4. The oxcarbazepine of claim **3** having a PXRD diffraction pattern substantially as depicted in figure 1.

5. A process for preparing oxcarbazepine Form B comprising the steps of:
   a) preparing a solution of oxcarbazepine in a mixture of dichloromethane and toluene, and
   b) evaporating the toluene and the dichloromethane leaving Form B as a residue.

6. The process of claim **5**, wherein the solution is prepared by dissolving oxcarbazepine in dichloromethane and adding the dichloromethane to toluene.

7. The oxcarbazepine Form B prepared by the process of claim **5**.

8. A process for preparing oxcarbazepine Form B comprising the steps of:
   a) preparing a solution of oxcarbazepine in toluene;
   b) heating the solution;

c) cooling the solution at a rate of 60°C min^{-1} or above to cause formation of a precipitate; and

d) separating the precipitate.

9. The process of claim **8**, wherein the solution is heated to about reflux.

10. The process of claim **8**, wherein the solution is cooled to a temperature of about 0°C.

11. The oxcarbazepine Form B prepared by the process of claim **8**.

12. Oxcarbazepine Form C.

13. Oxcarbazepine characterized by PXRD peaks at about 11.7, 21.7, 23.2, 24.4 ± 0.2 degrees two-theta

14. The oxcarbazepine of claim **13** characterized by PXRD peaks at about 11.7, 17.0, 18.0, 21.7, 23.2, 24.4, 26.0 ± 0.2 degrees two-theta.

15. The oxcarbazepine of claim **14** characterized by a PXRD diffraction pattern substantially as depicted in figure 2.

16. A process for preparing oxcarbazepine Form C comprising the steps of:

a) preparing a solution of oxcarbazepine in toluene;

b) heating the solution;

c) cooling the solution at a rate of from about 20 to 60°C $min.^{-1}$ to cause formation of a precipitate; and

d) separating the precipitate.

17. The process of claim **16**, wherein the solution is cooled at a rate of about 40°C

per minute.

18. The process of claim **16**, wherein the solution is cooled to about 0°C.

19. The process of claim **16**, wherein the solution is heated to about reflux.

20. The oxcarbazepine Form C prepared by the process of claim **16**.

21. Oxcarbazepine Form D.

22. Oxcarbazepine characterized by PXRD peaks at about 11.7, 14.2, 24.3 ± 0.2 degrees two-theta.

23. The oxcarbazepine of claim **22** characterized by a PXRD diffraction pattern substantially as depicted in figure 3.

24. A process for preparing oxcarbazepine Form D comprising the steps of:
    a) preparing a solution of oxcarbazepine in toluene; and
    b) evaporating the toluene leaving a residue of oxcarbazepine Form D.

25. The process of claim **24**, further comprising a step of heating the solution before evaporating.

26. The process of claim **25**, wherein the solution is heated to about reflux.

27. The process of claim **25**, further comprising cooling the heated solution before evaporating.

28. The process of claim **27**, wherein the solution is cooled to about 0°C.

29. The process of claim **24**, further comprising a step of cooling the solution.

30. The process of claim **29**, wherein the solution is cooled to about 0°C.

31. The process of claim **24**, wherein the toluene is removed from the solution by evaporation.

32. The oxcarbazepine Form D prepared by the process of claim **24**.

33. An oxcarbazepine chloroform solvate.

34. Oxcarbazepine chloroform solvate Form E.

35. An oxcarbazepine chloroform solvate characterized by a PXRD pattern with peaks at about 14.5, 15.0, 18.2, 21.4, 22.9, 24.0, 25.8, 26.0 ± 0.2 degrees two-theta.

36. The oxcarbazepine solvate of claim **35** characterized by a PXRD diffraction pattern substantially as depicted in figure 4.

37. The oxcarbazepine chloroform solvate of claim **33** containing about a 27 weight % chloroform.

38. A process for preparing oxcarbazepine chloroform solvate comprising:
    a) causing formation of a precipitate from a solution of oxcarbazepine in chloroform, and
    b) separating the precipitate.

39. The process of claim **38**, further comprising a step of heating the solution before causing formation of the precipitate.

40. The process of claim **39**, further comprising a step of cooling the heated solution, whereby cooling causes formation of the precipitate.

41. The process of claim **39**, wherein the solution is heated to an elevated temperature of from about 50°C to about 60°C.

42. The process of claim **41**, wherein the solution is heated to an elevated temperature of about 55°C.

43. The process of claim **41**, wherein the heated solution is cooled to a reduced temperature of from about 10°C to about 20°C.

44. The process of claim **43**, wherein the reduced temperature is about 16°C.

45. The oxcarbazepine chloroform solvate produced by the process of claim **37**.

46. A process for preparing oxcarbazepine Form A comprising:
   a) providing oxcarbazepine chloroform solvate Form E,
   b) heating the oxcarbazepine chloroform solvate, and
   c) recovering oxcarbazepine as Form A.

47. The process of claim **46**, wherein the oxcarbazepine solvate Form E is heated to an elevated temperature in the range of from about 40°C to about 80°C.

48. The process of claim **47**, wherein the elevated temperature is about 60°C.

49. A process for preparing oxcarbazepine Form A comprising
   a) providing oxcarbazepine Form B,
   b) heating the oxcarbazepine, and

c) recovering the oxcarbazepine as Form A.

50. The process of claim **49**, wherein oxcarbazepine Form B is heated to an elevated temperature in the range of from about 60°C to about 120°C.

51. The process of claim **50**, wherein the elevated temperature is about 60°C.

52. A process for the preparation of oxcarbazepine Form C comprising

a) providing oxcarbazepine Form B,

b) maintaining the oxcarbazepine at a temperature in the range of from about 20 to about 30°C, and

c) recovering the oxcarbazepine as Form C.

53. A process for preparing oxcarbazepine Form A comprising:

a) contacting oxcarbazepine selected from the group consisting of oxcarbazepine Form B, oxcarbazepine Form C and oxcarbazepine Form D with a protic solvent; and

b) recovering oxcarbazepine as Form A.

54. The process of claim **53**, wherein the forms of oxcarbazepine are suspended in the protic solvent.

55. The process of claim **53**, wherein the protic solvent is selected from the group consisting of water and ethanol.

56. The process of claim **54**, wherein the oxcarbazepine is suspended in the protic solvent from about two hours to about three days.

57. The process of claim **56**, wherein the oxcarbazepine is suspended for about one day.

58. A pharmaceutical composition comprising:

a) oxcarbazepine selected from the group consisting of oxcarbazepine Form B, oxcarbazepine Form C, oxcarbazepine Form D and oxcarbazepine Form E; and

b) a pharmaceutically acceptable excipient.

59. The pharmaceutical composition of claim **58**, wherein the composition is mixed with one or more forms of oxcarbazepine.

60. A pharmaceutical dosage form comprising the pharmaceutical composition of claim **58**.

61. The pharmaceutical dosage form of claim **60**, wherein the dosage form is a capsule or tablet.

62. The pharmaceutical dosage form of claim **61**, wherein the dosage form is a tablet.

63. The pharmaceutical dosage form of claim **60**, containing a unit dosage of about 150mg to about 600mg oxcarbazepine.

64. The pharmaceutical dosage form of claim **63**, containing a unit dosage selected from the group consisting of about 150mg, 300mg and 600mg.

65. The pharmaceutical dosage form of claim **60**, wherein the dosage form is an oral suspension.

66. The pharmaceutical dosage form of claim **65**, wherein the dosage is about 60mg ml^{-1}.

67. The pharmaceutical dosage form of claim **66**, wherein the dosage is about 300mg ml^{-1}.

68. A method of preventing or reducing the severity of seizures comprising administrating the pharmaceutical composition of claim **58**.

69. The method of claim **68**, wherein the seizures are associated with epilepsy.

70. A method of treating Parkinson's disease comprising administrating the pharmaceutical composition of claim **58**.

71. A method of depressing the central nervous system comprising administering the pharmaceutical composition of claim **58**.

72. The method of claim **71**, wherein the central nervous system is depressed by blocking voltage sensitive sodium channels.